D
uring the past 4 decades, there has been a rapid increase in the incidence of esophageal adenocarcinoma (EA), such that EA is one of the fastest increasing cancers in incidence among Western populations. 1 Among white males in the United States, EA incidence has increased almost 10-fold and rates continue to increase.
2 Strikingly, 40% of EA patients in the United States still are diagnosed with distant stage disease, and less than 20% of all EA patients survive for 5 years after EA diagnosis. 2 Secondary prevention strategies offer the greatest promise for reducing EA burden because the precursor lesion, Barrett's esophagus (BE), is readily identifiable, the natural history of BE/EA are reasonably well defined, and treatment for dysplasia and early cancers is very effective. As such, current best practice is to screen via upper endoscopy to identify patients with BE, followed by endoscopic surveillance among those with BE to identify BE patients with neoplastic progression (dysplasia or early cancer) before they progress to invasive EA, and to apply endoscopic treatments. The simplicity of this strategy is enticing. Indeed, there is increasing evidence that BE diagnosis is linked to earlier tumor stage at EA diagnosis and better survival in EA. 3, 4 However, despite the greatly increased risk of EA, most BE patients never progress to neoplasia and most undergo unnecessary invasive and costly surveillance and treatment.
Remarkably, despite research efforts to identify additional risk factors for progression among BE patients, clinical practice has not taken advantage of the recognition of these risk factors to develop more sophisticated risk stratification for BE surveillance. Instead, strategies for secondary prevention of EA have, for the most part, not progressed beyond the simple strategy of risk stratification on the presence and degree of dysplasia ( Table 1) . As such, current clinical guidelines recommend that BE patients with high-grade dysplasia (HGD) should be referred to expert centers for endoscopic eradication therapy. For patients with confirmed low-grade dysplasia, endoscopic surveillance is recommended every 6 to 12 months in the absence of endoscopic therapy. However, there are no other criteria used to risk-stratify among subgroups of BE patients with low-grade dysplasia or HGD.
In the current clinical landscape, most patients under surveillance have benign, nondysplastic BE. Because the absolute risk of EA in patients with nondysplastic BE is low (0.1%-0.3% per year) and most nondysplastic BE patients die from non-EA-related causes, 5 surveillance intervals for these patients have been extended and current guidelines recommend surveillance endoscopy at 3-to 5-year intervals. Nonetheless, some of these patients progress to HGD or EA while being treated the same (ie, 3-to 5-year intervals) as the remainder who are at very low risk. To date, only the British Society of Gastroenterology and Australian clinical practice guidelines risk-stratify further among nondysplastic BE patients on the grounds of BE segment length. These guidelines recommend that patients with short-segment nondysplastic BE should have a follow-up endoscopy every 3 to 5 years, whereas it is every 2 to 3 years for patients with long-segment nondysplastic BE (Table 1) .
On this background, Hamade et al 6 reported in this issue of Clinical Gastroenterology and Hepatology the risk of EA in short-segment vs long-segment BE patients. Using data from 1883 patients with endoscopic evidence of nondysplastic BE followed up for a median of 6.4 years at 7 tertiary referral centers, the annual rate of progression to HGD or EA was significantly lower in patients with short-segment BE than long-segment BE (0.29% vs 0.91%; P < .001). After adjusting for other prognostic factors such as age, sex, smoking, body mass index, and hiatal hernia, the risk of progression was 3 times lower in patients with short-segment BE (hazard ratio, 0.32; 95% CI, 0.18-0.57) compared with patients with longsegment BE. Patients with segment length less than 1 cm were excluded from the main analysis, although it is interesting to note that no events were noted in these patients. This was a large analysis within patients with known BE segment length and confirms prior observations. Therefore, the study provides further support for tailoring surveillance intervals based on BE segment length, as currently recommended by British and Australian guidelines. The question that remains to be answered, is whether the best way of tailoring guidelines is to reduce surveillance intervals with long-segment BE or extend surveillance intervals of patients with shortsegment BE.
Another area of increasing interest is risk stratification for BE surveillance according to persistence of nondysplastic BE. In particular, is there a point in time at which persistence of nondysplastic BE is protective against progression to EA, and, if so, should surveillance intervals be extended among this subgroup of BE patients? In another study published in this issue of Clinical Gastroenterology and Hepatology, Peters et al 7 used data from 12,728 patients with nondysplastic BE selected from the Dutch nationwide registry of histopathology. The investigators grouped patients according to the number of successive endoscopies negative for dysplasia and assessed and compared the risk of HGD or EA in BE patients across these groupings. By using multivariate Poisson regression, the risk of malignant progression after at least 2 or 3 consecutive endoscopies showing nondysplastic BE was lower than after only 1 endoscopy showing nondysplastic BE (incidence rate ratio, 0.30; 95% CI, 0.24-0.38 after 2 endoscopies; and incidence rate ratio, 0.25; 95% CI, 0.16-0.39 after 3 endoscopies). Peters et al 7 suggested that the lower odds of progression after multiple endoscopies negative for dysplasia may reflect lower odds of missing dysplasia at multiple endoscopies. The high rate of progression after only 1 endoscopy showing nondysplastic BE therefore may be an artifact of dysplasia missed at the initial endoscopy. The results also indicated that the number of subsequent endoscopies needed to detect 1 EA/HGD increased from 29 after 1 endoscopy to 57 after 3 consecutive endoscopies negative for dysplasia. The investigators argued that these results indicated that the risks of continued surveillance may outweigh the benefits in this instance and that surveillance could be lengthened or discontinued in patients with persistent nondysplastic BE. However, the evidence from previous studies is mixed, [8] [9] [10] so more evidence may be required before alterations to guidelines should be considered.
Conclusions
There is an imperative to identify BE patients who are never likely to progress to HGD or EA, so that they can be spared the hazards of unwarranted and harmful intervention. Incorporating BE segment length and, with further evidence, history of persistent nondysplastic BE into risk stratification for BE surveillance are a first step toward achieving this goal. However, there may be a role of additional factors in predicting which patients with BE are at low, intermediate, or high risk and tailoring intervals to match absolute risk of progression. 11 Additional focus should be given to better risk stratification among the large pool of nondysplastic BE patients under surveillance. 
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